Global Choroidal Neovascularization Market 2016-2020

  • ID: 3623664
  • Report
  • Region: Global
  • 56 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Alcon
  • Bausch and Lomb
  • Gilead Sciences
  • Neurotech Pharmaceuticals
  • Ophthotech
  • Pfizer
  • MORE
About Choroidal Neovascularization

Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).

The analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors:

- Bayer HealthCare
- Novartis
- Regeneron Pharmaceuticals
- F. Hoffmann-La Roche

Other prominent vendors:

- Alcon
- Allergan
- Avalanche
- Bausch and Lomb
- Gilead Sciences
- Iconic Therapeutics
- Lpath
- Neurotech Pharmaceuticals
- Ohr Pharmaceutical
- Opthea
- Ophthotech
- PanOptica
- Pfizer
- Promedior
- QLT
- Quark
- Resolvyx Pharmaceuticals
- RXi Pharmaceuticals
- Sagent Pharmaceuticals
- Santen
- Sanwa Kagaku Kenkyusho

Market drivers

- Growing older population
- For a full, detailed list, view the full report

Market challenges

- High cost of treatment
- For a full, detailed list, view the full report

Market trends

- Strategic alliances and M&A
- For a full, detailed list, view the full report

Key questions answered in this report

- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alcon
  • Bausch and Lomb
  • Gilead Sciences
  • Neurotech Pharmaceuticals
  • Ophthotech
  • Pfizer
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Key buying criteria
PART 05: Disease overview
  • Introduction
  • Pathophysiology
  • Symptoms
  • Management
  • Epidemiology
PART 06: Product portfolio of approved therapies

PART 07: Pipeline analysis
  • OHR-102
  • RTH258
  • Fovista
  • RG7716
  • PF-04523655
  • NT-503
  • LFG316
  • REGN2176-3
  • Zimura
  • LHA510
  • DE-120
PART 08: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 09: Market segmentation by ROA
  • IV
  • Intravitreal
PART 10: Geographical segmentation
  • Global choroidal neovascularization market by geographical segmentation 2015-2020
  • Choroidal neovascularization market in Americas
  • Choroidal neovascularization market in EMEA
  • Choroidal neovascularization market in APAC
PART 11: Market drivers
  • Growing older population
  • Increased prevalence of chronic diseases
  • High patient and physician satisfaction
  • Increase in diagnosis rate
PART 12: Impact of drivers

PART 13: Market challenges
  • High cost of treatment
  • Limited public awareness
  • Side effects associated with treatment options
  • Availability of alternative therapies
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Strategic alliances and M&A
  • Increased initiatives and programs
  • Use of combination therapies
  • Increase in R&D
PART 16: Vendor landscape
  • Competitive scenario
  • Market analysis 2015
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Bayer HealthCare
  • Other prominent vendors
PART 17: Appendix
  • List of abbreviations
PART 18: About Author

List of Exhibits

Exhibit 01: Product offerings 7
Exhibit 02: Key buying criteria for choroidal neovascularization drugs
Exhibit 03: Types of choroidal neovascularization
Exhibit 04: Symptoms of choroidal neovascularization
Exhibit 05: Treatment options for choroidal neovascularization
Exhibit 06: Pipeline portfolio: Global choroidal neovascularization therapeutics
Exhibit 07: Global choroidal neovascularization market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global choroidal neovascularization market by ROA 2015
Exhibit 10: Market segmentation by geography 2015
Exhibit 11: Choroid neovascularization market revenue by geography 2015-2020 ($ billions)
Exhibit 12: Choroidal neovascularization market in Americas 2015-2020 ($ billions)
Exhibit 13: Choroidal neovascularization market in EMEA 2015-2020 ($ billions)
Exhibit 14: Choroidal neovascularization market in APAC 2015-2020 ($ millions)
Exhibit 15: Global choroidal neovascularization market: YoY growth and revenue based on geography 2015-2020
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Vendor ranking of global choroidal neovascularization market 2015
Exhibit 19: Roche: YoY growth and revenue of Avastin 2011-2014 ($ billions)
Exhibit 20: Roche: YoY growth and revenue of Lucentis 2011-2014 ($ billions)
Exhibit 21: Roche: Key takeaways
Exhibit 22: Novartis' specialty ophthalmic segmentation by revenue 2014
Exhibit 23: Novartis: YoY revenue and growth rate of Lucentis (excluding the US) 2012-2014 ($ millions)
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Regeneron: YoY revenue and growth rate of EYLEA (in the US) 2012-2014 ($ billions)
Exhibit 26: Regeneron Pharmaceuticals: Key takeaways
Exhibit 27: Bayer HealthCare: YoY revenue and growth rate of EYLEA 2012-2014 ($ millions)
Exhibit 28: Bayer HealthCare: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alcon
  • Bausch and Lomb
  • Gilead Sciences
  • Neurotech Pharmaceuticals
  • Ophthotech
  • Pfizer
  • MORE
New Report Released: – Global Choroidal Neovascularization Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Choroidal Neovascularization Market: Bayer HealthCare, Novartis, Regeneron Pharmaceuticals and F. Hoffmann-La Roche.

Other Prominent Vendors in the market are: Alcon, Allergan, Avalanche, Bausch and Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior, QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen and Sanwa Kagaku Kenkyusho.

Commenting on the report, an analyst from the research team said: “The market presents significant growth opportunities for vendors. Companies are increasingly forming strategic alliances and engaging in M&A to increase their market share. As the development cost of ophthalmic drugs is high, small biotechnology firms are forming alliances with big pharmaceutical companies for product development.”

According to the report, Better infrastructure in terms of healthcare facilities and sophisticated treatment options has led to a rise in the life expectancy rates, leading to a rise in the number of people over 60 years. The normal aging process results in reduced choroidal blood flow, which leads to ischemia. This, in turn, leads to increased expression of VEGF and development of excess blood vessels resulting in choroidal neovascularization and finally the loss of vision. With the increase in older population, the demand for choroidal neovascularization drugs is also increasing.

Further, the report states that High cost of treatment restricts the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Bayer HealthCare
- Novartis
- Regeneron Pharmaceuticals
- F. Hoffmann-La Roche
- Alcon
- Allergan
- Avalanche
- Bausch and Lomb
- Gilead Sciences
- Iconic Therapeutics
- Lpath
- Neurotech Pharmaceuticals
- Ohr Pharmaceutical
- Opthea
- Ophthotech
- PanOptica
- Pfizer
- Pr
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll